A multicenter, prospective, exploratory study evaluating an all-oral combination of Ivosidenib, Sonrotoclax, and Chidamide for the treatment of newly diagnosed IDH1-mutated acute myeloid leukemia (ChiCTR) - Oct 16, 2026 - P2 | N=30 | Not yet recruiting | Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
New P2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • IDH1
|